Key Highlights
- Diaceutics (LSE:DXRX) rose 1.83% on 2 October 2026, trading close to its 52-week high of around 193p.
- H1 2026 Revenue rose 20% to £17.5 million, or 22% at constant currency, with Gross Profit up 23% to £14.9 million.
- Gross Margin expanded to 85%, and the order book grew 38% to £43.7 million, with £15.7 million contracted for H2 delivery.
- The company expanded its Relay Partnership with Syndax on 24 September and launched an NGS concordance study in August.
- A refreshed corporate positioning as the intelligence and engagement company for diagnostic-driven therapies was launched in September.
Diaceutics (LSE:DXRX) Builds on Strong Results Momentum
Shares in Diaceutics PLC (LSE:DXRX), the intelligence and engagement company serving the pharmaceutical industry's precision medicine efforts, rose 1.83% on Friday 2 October 2026. The stock has been trading near the top of its 52-week range of roughly 125p to 193p following a well-received set of interim results and a fresh commercial partnership expansion.
The continued buying suggests investors increasingly view Diaceutics as a scalable, high-margin data and services platform at an inflection point in recurring revenue.
Key Reasons Behind the 1.83% Gain
The first driver is the strength of the interim results published on 22 September. Revenue increased 20% to £17.5 million in H1 2026, or 22% on a constant currency basis. Gross profit rose 23% to £14.9 million, with gross margin expanding to 85%. Management said the results reflect continued execution of a strategy to build a higher-quality, more predictable and more scalable business.
The second driver is visibility. The order book increased 38% to £43.7 million, with £15.7 million already contracted for delivery in the second half of 2026. That level of contracted work gives investors confidence in full-year forecasts and supports the shift towards recurring revenue.
The third driver is partnership momentum. On 24 September, Diaceutics announced an expanded Relay partnership with Syndax, a commercial-stage biopharmaceutical company, broadening the scope of its engagement services. In August, Diaceutics and a pathology partner launched an NGS concordance study, highlighting its role in improving the quality and consistency of next-generation sequencing tests that guide treatment decisions.
Why Investors Are Watching LSE:DXRX
Diaceutics operates the DXRX platform, which combines diagnostic testing data from a network of laboratories with analytics and engagement services. Pharmaceutical companies use the platform to understand where patients are being tested, identify gaps in diagnostic pathways and ensure eligible patients are identified for targeted therapies. As more precision medicines reach the market, effective diagnostic testing becomes critical to commercial success.
In September the company formally launched refreshed positioning under the proposition of being the intelligence and engagement company unlocking the full potential of diagnostic-driven therapies. Management has emphasised cash generation as a key focus and an important validation point for its shift towards sustainable profitability.
Investors are also watching whether margin expansion and the growing order book translate into consistent positive free cash flow, which would mark a significant milestone for the business.
Market and Social Media Sentiment
Investor commentary on LSE:DXRX has been positive since the interim results, with particular praise for the 85% gross margin and the jump in the order book. Healthcare-focused research notes highlighted the results among the sector's key updates in September. Momentum traders have also been attracted by the stock's approach to its 52-week high.
Some investors remain cautious about the timing of conversion from order book to revenue and the dependence on pharmaceutical launch schedules, which can slip.
Upcoming Catalysts
Key catalysts include further pharmaceutical partnership announcements, a full-year 2026 trading update expected in January 2027, and evidence of Operating Leverage and cash generation in the second half.
Risks to Monitor
Risks include delays in drug launches, client concentration, competition in healthcare data analytics, and data access and privacy regulations.






Please wait processing your request...